促进药物性肝损伤的转化研究  

Promoting translational research on drug-induced liver injury

作　　者：茅益民 

机构地区：[1]上海交通大学医学院附属仁济医院上海市消化疾病研究所,200001

出　　处：《中华肝脏病杂志》2016年第11期807-809,共3页Chinese Journal of Hepatology

基　　金：“十二五”科技重大专项（2012ZX09303-001）;国家自然科学基金课题面上项目（81670524）;上海交通大学医学院多中心临床研究项目

摘　　要：药物性肝损伤（DILI）是最重要的药源性疾病之一，也是药物审批失败、增加警示以及撤市的重要原因，其临床表型复杂，可引起几乎所有的急性、亚急性和慢性肝损伤类型，重者可导致肝功能衰竭，甚至死亡。涉及的药物种类多样，人群异质性复杂，都是临床上导致多数DILI病例不可预测的原因。因此，DILI的预测、诊断和治疗，成为了肝病领域中极具挑战性的问题。加强这方面的临床转化研究，使更多成果转化为临床诊断、治疗的真正手段，具有重要的意义。Drag-induced liver injury （DILI） is one of the most important drug-induced diseases and an important reason for failure to obtain approval, an increase in warnings, and withdrawal from market. DILI has a complex clinical phenotype and can cause almost all types of acute, subacute, and chronic liver injury, and it may cause liver failure and even death in patients with severe conditions. The diversity of drugs involved and heterogeneity of populations are the main reasons for unpredictability of most DILl cases in clinical practice. Therefore, the prediction, diagnosis, and treatment of DILI become challenging issues in the field of liver disease, and it is of great significance to strengthen clinical translational research in this aspect, so as to transform more achievements into actual diagnostic and treatment methods.

关 键 词：肝炎 慢胜 药物性 转化 研究 

分 类 号：R575[医药卫生—消化系统]